Haemonetics Corporation (HAE) Q1 2026 Earnings Call Transcript

Haemonetics Corporation (NYSE:HAE) initiated its Q1 Fiscal Year 2026 earnings conference call on August 7, 2025, concurrently releasing its first-quarter results and full-year fiscal 2026 guidance. The company specified that its financial update would emphasize both reported and organic revenue growth, explicitly excluding the effects of foreign exchange, the whole blood business divestiture, the exit of liquid solution products, and the CSL U.S. disposables business transition, aiming to provide a refined perspective on underlying business performance.

Analysis

Haemonetics Corporation (HAE) has initiated its first-quarter fiscal 2026 earnings call by directing attention to a specific set of adjusted performance metrics. Management emphasized that its discussion of results and full-year guidance will focus on organic revenue growth, a non-GAAP figure that excludes the impacts of foreign exchange, the divestiture of the whole blood business, the exit of liquid solution products, and the transition of its U.S. disposables business with CSL. This framing suggests that reported top-line results are materially impacted by these strategic and transitional activities. By providing this specific definition of organic growth upfront, the company is guiding investors to evaluate the underlying health and go-forward potential of its core operations, stripped of the statistical noise from recent restructuring and a major customer contract change.

Key Decisions for Investors

• Investors should prioritize analyzing the reconciliation between reported and organic revenue to precisely quantify the financial impact of the divested businesses and the CSL contract transition.
• The core investment thesis should be evaluated based on the strength and outlook for the company's organic growth, as this represents management's view of the ongoing business's fundamental health.
• Carefully monitor management's commentary for any changes in the full-year 2026 guidance and for further details on the margin and revenue implications of the strategic exits and customer-related adjustments.